Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.25
-$0.17-2.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.18% | 49.20% | 81.38% | -25.31% | 19.06% |
| Total Depreciation and Amortization | 19.40% | 21.93% | -18.48% | -1.82% | -32.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.86% | -52.24% | -83.93% | 16.56% | -32.43% |
| Change in Net Operating Assets | -3,806.73% | -94.82% | -5,272.11% | 149.49% | -79.03% |
| Cash from Operations | 42.28% | 26.62% | -40.72% | -14.76% | 1.46% |
| Capital Expenditure | -13.59% | -297.85% | -244.42% | -99.75% | 65.49% |
| Sale of Property, Plant, and Equipment | -- | -96.01% | 440.54% | -93.47% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 133.89% | 384.77% | -- | -- |
| Cash from Investing | -1,540.66% | 71.97% | -201.69% | -139.14% | 37.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 29.59% | 36.16% | 39.21% | 38.65% | 8.70% |
| Issuance of Common Stock | -- | -100.00% | -100.00% | 16.67% | 483.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -546.34% | 96.25% | -7.44% |
| Cash from Financing | 75.50% | 67.88% | -47.62% | 83.64% | 4.84% |
| Foreign Exchange rate Adjustments | 147.13% | -171.57% | 82.05% | 96.59% | -503.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.54% | 46.88% | -47.47% | -28.71% | 7.70% |